- Previous Close
2,328.35 - Open
2,347.90 - Bid 2,318.95 x --
- Ask 2,322.00 x --
- Day's Range
2,310.30 - 2,365.20 - 52 Week Range
1,014.45 - 2,643.50 - Volume
9,558 - Avg. Volume
18,627 - Market Cap (intraday)
95.115B - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
77.97 - EPS (TTM)
29.80 - Earnings Date --
- Forward Dividend & Yield 3.00 (0.13%)
- Ex-Dividend Date Sep 13, 2024
- 1y Target Est
2,489.40
Ami Organics Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications, as well as in new chemical entities. It also provides specialty chemicals for use in agrochemicals, cosmetics, and polymers; and parabens and parabens formulation, salicylic acid, and other special chemicals that are used in cosmetics, dyes, polymers and agrochemical, animal foods, and personal care industries. Ami Organics Limited exports its products. The company was founded in 2004 and is based in Surat, India.
www.amiorganics.com676
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: AMIORG.BO
View MorePerformance Overview: AMIORG.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMIORG.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMIORG.BO
View MoreValuation Measures
Market Cap
95.12B
Enterprise Value
92.38B
Trailing P/E
78.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.73
Price/Book (mrq)
7.91
Enterprise Value/Revenue
10.05
Enterprise Value/EBITDA
45.63
Financial Highlights
Profitability and Income Statement
Profit Margin
13.15%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
9.23B
Net Income Avi to Common (ttm)
1.21B
Diluted EPS (ttm)
29.80
Balance Sheet and Cash Flow
Total Cash (mrq)
2.8B
Total Debt/Equity (mrq)
0.51%
Levered Free Cash Flow (ttm)
--